ZBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zenas Biopharma Inc (ZBIO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts like insider buying and promising pipeline updates, the technical indicators are bearish, financial performance is weak, and options sentiment leans negative. Given the investor's background and preference for long-term stability, it is better to hold off on investing in ZBIO until stronger positive signals emerge.
The technical indicators for ZBIO are bearish. The MACD is negatively expanding below 0, the RSI is neutral at 21.934, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 18.193 and resistance at 20.397.
Insider buying has increased significantly by 165.23% over the last month.
Analysts from Guggenheim and Wedbush have issued positive ratings, citing pipeline updates and potential FDA approval for key drugs.
The company's gross margin remains strong at 100%.
Financial performance is weak, with revenue dropping to 0 (-100% YoY) and EPS declining by -51.81% YoY.
The stock's technical indicators are bearish, and it has a 70% chance of declining -7.09% in the next day.
Options sentiment leans bearish, with a high put-call volume ratio and low implied volatility rank.
In Q4 2025, ZBIO reported a revenue drop to 0 (-100% YoY), net income improved to -$240.44M (+357.08% YoY), and EPS dropped to -4.53 (-51.81% YoY). Gross margin remained stable at 100%.
Analysts are mixed but leaning positive. Citi lowered the price target to $41 from $43 but maintained a Buy rating. Morgan Stanley raised the price target to $21 from $19 with an Equal Weight rating. Guggenheim raised the price target to $55 from $45 with a Buy rating, citing pipeline updates. Wedbush added ZBIO to its Best Ideas List, highlighting a clinically de-risked drug with strong commercial potential.
